UMB Bank n.a. acquires 553 shares of Exelixis, Inc. (NASDAQ:EXEL).

2 min read | January 26, 2025 01:08 AM PST | By Team Kalkine Media

UMB Bank n.a. acquires 553 shares of Exelixis, Inc. (NASDAQ:EXEL).

Institutional Investment Surge

UMB Bank n.a. raised its stake in Exelixis, Inc. (NASDAQ:EXEL) by 68.4% in the fourth quarter, reflecting robust institutional interest in the biotechnology company. At the end of the quarter, UMB Bank held 1,361 shares valued at $45,000, having purchased an additional 553 shares. This move aligns with trends observed across various institutional investors and hedge funds.

Other entities, including V Square Quantitative Management LLC, USA Financial Formulas, and Brooklyn Investment Group, recently acquired positions in Exelixis, showing confidence in the stock’s potential. With roughly 85.27% of Exelixis shares held by institutional investors and hedge funds, the company holds a strong position within the investment community.

Financial Performance

Exelixis reported robust earnings for the last quarter, with earnings per share of $0.40, surpassing the consensus estimate of $0.36. The revenue reached $539.50 million, up 14.3% from the previous year, and exceeded analyst expectations. The company’s net margin stood at 22.43% with a return on equity of 20.99%, signaling financial stability and growth.

With its portfolio including treatments like CABOMETYX and COMETRIQ, Exelixis is well-positioned in the oncology sector. Analysts forecast an annual EPS of 1.74 for the current fiscal year, further emphasizing the company’s strong performance trajectory.

Insider Activities

Recent insider transactions have involved strategic sales by executives Dana Aftab and Patrick J. Haley. Aftab sold 1,162 shares, while Haley sold 41,588 shares, indicating a reduction of their holdings by 0.23% and 12.59% respectively. These transactions highlight typical practices within the corporate environment to balance personal investments while still maintaining substantial stakes.

Overall, insiders continue to retain confidence in the company, collectively holding 2.85% of Exelixis stock.

Company Overview

Exelixis, a leader in the biotechnology sector, primarily focuses on developing and commercializing oncology treatments. The company’s innovative products target difficult-to-treat cancers, enhancing its reputation and market position within the United States and abroad.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.